1. Small interfering RNA for cancer treatment: overcoming hurdles in delivery
- Author
-
Charbe, NB, Amnerkar, ND, Ramesh, B, Tambuwala, MM, Bakshi, HA, Aljabali, AAA, Khadse, SC, Satheeshkumar, R, Satija, S, Metha, M, Chellappan, DK, Shrivastava, G, Gupta, G, Negi, P, Dua, K, Zacconi, FC, Charbe, NB, Amnerkar, ND, Ramesh, B, Tambuwala, MM, Bakshi, HA, Aljabali, AAA, Khadse, SC, Satheeshkumar, R, Satija, S, Metha, M, Chellappan, DK, Shrivastava, G, Gupta, G, Negi, P, Dua, K, and Zacconi, FC
- Abstract
© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.
- Published
- 2020